OBJECTIVES: The prevalence of idiopathic pulmonary fibrosis (IPF) tends to be greater in the elderly although the precise outcome is not known. The present study investigated the outcome of IPF in elderly patients whose pathological diagnosis corresponded to usual interstitial pneumonia (UIP) on autopsy findings. METHODS: In a consecutive autopsy series, (n = 4,554 cases), complete information was obtained in 86 cases in which the clinical and pathological diagnosis was IPF and UIP, respectively. RESULTS: Mean subject age was 80.5 years and there were 52 males and 34 females. Median survival time (MST) was 3.5 years overall. Dyspnea ranking by the MRC dyspnea scale (DR) on admission was closely related to the outcome. When MST was compared between DR0 and DR1, or DR2 and DR3, the former patient group survived significantly longer than the latter (p < 0.05). Twenty percent of patients died of severe respiratory failure. Other causes of death were disease progression of IPF (10.5%), bacterial pneumonia (23.3%) and lung cancer (17.4%). The patients in the young-elderly group (age < 75) survived for a significantly longer period than those in the old-elderly group (age > or = 75) (MST; 5.5 vs 2.0 years; p < 0.001). Both lung cancer and pneumonia were significantly more prevalent among IPF patients than among non-IPF patients; these IPF with lung cancer profoundly reflected the smoking history of IPF patients. CONCLUSIONS: The poor outcome in IPF in elderly patients was characterized by more severe dyspnea, advanced age and co-morbidity.
OBJECTIVES: The prevalence of idiopathic pulmonary fibrosis (IPF) tends to be greater in the elderly although the precise outcome is not known. The present study investigated the outcome of IPF in elderly patients whose pathological diagnosis corresponded to usual interstitial pneumonia (UIP) on autopsy findings. METHODS: In a consecutive autopsy series, (n = 4,554 cases), complete information was obtained in 86 cases in which the clinical and pathological diagnosis was IPF and UIP, respectively. RESULTS: Mean subject age was 80.5 years and there were 52 males and 34 females. Median survival time (MST) was 3.5 years overall. Dyspnea ranking by the MRC dyspnea scale (DR) on admission was closely related to the outcome. When MST was compared between DR0 and DR1, or DR2 and DR3, the former patient group survived significantly longer than the latter (p < 0.05). Twenty percent of patients died of severe respiratory failure. Other causes of death were disease progression of IPF (10.5%), bacterial pneumonia (23.3%) and lung cancer (17.4%). The patients in the young-elderly group (age < 75) survived for a significantly longer period than those in the old-elderly group (age > or = 75) (MST; 5.5 vs 2.0 years; p < 0.001). Both lung cancer and pneumonia were significantly more prevalent among IPF patients than among non-IPF patients; these IPF with lung cancer profoundly reflected the smoking history of IPF patients. CONCLUSIONS: The poor outcome in IPF in elderly patients was characterized by more severe dyspnea, advanced age and co-morbidity.
Authors: Evan A Elko; J Matthew Mahoney; Pamela Vacek; Albert van der Vliet; Vikas Anathy; Jos L J L van der Velden; Yvonne M W Janssen-Heininger; David J Seward Journal: Free Radic Biol Med Date: 2019-07-14 Impact factor: 7.376
Authors: Louise Hecker; Naomi J Logsdon; Deepali Kurundkar; Ashish Kurundkar; Karen Bernard; Thomas Hock; Eric Meldrum; Yan Y Sanders; Victor J Thannickal Journal: Sci Transl Med Date: 2014-04-09 Impact factor: 17.956
Authors: Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli Journal: Respir Med Date: 2016-06-02 Impact factor: 3.415
Authors: Heather W Stout-Delgado; Soo Jung Cho; Sarah G Chu; Dana N Mitzel; Julian Villalba; Souheil El-Chemaly; Stefan W Ryter; Augustine M K Choi; Ivan O Rosas Journal: Am J Respir Cell Mol Biol Date: 2016-08 Impact factor: 6.914
Authors: Joseph Jacob; Brian J Bartholmai; Srinivasan Rajagopalan; Coline H M van Moorsel; Hendrik W van Es; Frouke T van Beek; Marjolijn H L Struik; Maria Kokosi; Ryoko Egashira; Anne Laure Brun; Arjun Nair; Simon L F Walsh; Gary Cross; Joseph Barnett; Angelo de Lauretis; Eoin P Judge; Sujal Desai; Ronald Karwoski; Sebastien Ourselin; Elisabetta Renzoni; Toby M Maher; Andre Altmann; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2018-09-15 Impact factor: 30.528